本帖最后由 老马 于 2012-1-13 21:20 编辑
% _# x R0 d% Y8 y3 x' d; [/ f& g+ Z3 J, F6 j
爱必妥和阿瓦斯丁的比较
$ ?" L! e# e( D
, Z; y% Z" j3 ^( ~+ z) `9 Q! ehttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# Q8 S0 B& H% @; b- H( E2 E8 `
+ C/ m+ J# [* C* n) Z
$ S, d" o) @4 i1 ?
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 `9 R+ R8 ]$ [4 c3 u==================================================
# [, D7 m6 W% ~2 a# J# YOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 Z$ j" U5 `, @7 H: h& Y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. w- b1 D2 ?% O/ q" M! \7 _5 B# P1 Z9 JResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% v# T* _' z. |" x1 V% @# j- c+ X! H
|